 Distribution of high-risk HPV types in Yugoslav women with cervical neoplasm
Z Magica, J Stojanovic a, D Nenadic b, M Orlic-Milacic a, B Stanimirovicc
Institute for Medical Research-MMA a, Ginecological Clinic- MMA b, Belgrade Ginecolgical and Obstetrics Clinic 'Narodni Front' c, Belgrade, Yugoslavia
The incidence of cervical neoplasm in population of Yugoslav women is very high. Thus, one of the ways to prevent cervical carcinoma is early detection and treatment of preinvasive stages. That underlies the need to evaluate the HPV typing in cervical cancer screening. The aim of this study was to determine the frequency of infection with cancerogenic types of human papillomavirus (HPV16, HPV18, HPV31 and HPV33) at the group of women previously diagnosed for different grades of cervical intraepithelial neoplasia. Patients and methods. The samples of cervical swab of 40 patients with a LSIL diagnosis, 3 patients with HSIL and 2 patients with cervicitis with coilocytosis were obtained. Integrated viral DNA was detected in genomic DNA of patients using PCR method. We used type-specific primer pairs for HPV16, HPV18, HPV31 and HPV33, which are specific for the E6, L1, E4 and E1 regions of viral genome, respectively. Results. The median age of patients was 31 year; all patients are sexually active. Eighteen of 45 patients are HPV positive and two of them are double positives. The infection with HPV31 is the most frequent in the population of Yugoslav women with CIN in contrast to literature data that HPV16 and HPV18 are most common high risk HPV types (seven of the HPV positive patients are infected with HPV31, five with HPV16, four with HPV18, one patient is HPV16/HPV31 double positive and one HPV18/HPV31 double positive. Maximal number of lifetime sexual partners in the group of HPV negative patients was 5, and in the group of HPV positive patients were 10. Conclusion. The PCR technique with type-specific primer pairs for the identification of HPV genome in cervical swab cells is sensitive and efficient method for PCR-HPV testing that can be used to improve both the effectiveness and cost of cervical screening.
For more information, contact vmiami@eunet.yu
Paper presented at the International Symposium on Predictive Oncology and Intervention Strategies; Paris, France; February 9 - 12, 2002; in the section on Viral Oncogenesis.
This presentation was a winner in our poster contest and was recognized with the Symposium Presidents' Award for Scientific Excellence.
http://www.cancerprev.org/Journal/Issues/26/101/996/4358
|
